Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Pleural Effusion, Malignant 4Breast Neoplasms 4Immunoglobulin Light-chain Amyloidosis 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Pancreatic Neoplasms 2Neoplasm Metastasis 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Exanthema 2Amyloidosis 2Waldenstrom Macroglobulinemia 1Urologic Neoplasms 1Tuberous Sclerosis 1Triple Negative Breast Neoplasms 1Tissue Adhesions 1Skin Toxicity 1Sezary Syndrome 1Ras-wildtype Colorectal Cancer 1Polyps 1Polycystic Ovary Syndrome 1Pain 1Ovarian Neoplasms 1Neurofibromatosis 2 1Neoplasms, Second Primary 1Neoplasms 1Myoma 1Menstruation Disturbances 1Melanoma 1

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236Cyclophosphamide 135aldesleukin 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 68dabrafenib 65fludarabine phosphate 62sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35Magnetic Resonance Spectroscopy 33cobimetinib 32Specimen Handling 31Introns 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Melanoma × Doxycycline × Clear all
NCT01590082 2020-09-02

Doxycycline, Temozolomide and Ipilimumab in Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
12 enrolled 6 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡